demonstrated the safety and efficacy of ex vivo expanded ILC2s (Ex ILC2s) in AML models, showing tumor cell killing through GzmB without inducing cytokine release syndrome or neurotoxicity (218). Here, GZMB is linked to acute myeloid leukemia.